| | | | | | | | | | |
|
| |
|
| Dockets Entered On August
4, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1995N-0205
|
| OTC Bronchodilator Drug Products
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
|
|
| 2004N-0564
|
| Agency Information Collection Activities; Proposed Collection; Temporary Marketing Permit Applications
|
|
|
|
|
| 2005D-0155
|
| Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
|
|
|
|
|
| 2005D-0203
|
| Guidance for Industry on Safety Testing of Drug Metabolites
|
|
|
|
|
| 2005N-0290
|
| Agency Information Collection Activities: Proposed Collection; Comment Request;
|
|
|
|
|
| 2005N-0299
|
| Authorization of Emergency Use of Anthrax Vaccine Adsorbed for Prevention of Inhalation Anthrax by Individuals at Heightened Risk of Exposure Due to Attack With Anthrax; Extension; Availability
|
|
|
|
|
|
| 2005Q-0298
|
| Qualified Health Claim (QHC): 100% Whey Protein Hydrolyzed in Infant Formula and Reduced Risk of Allergy in Infants
|
|
| |
|
| 1995N-0205
|
| OTC Bronchodilator Drug Products
|
|
|
|
|
| C 126
|
| T. Tiedt, PhD
|
| Vol #:
|
| 7
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET
16475
|
| Enzymatic Therapy
|
| Vol #:
|
| 147
|
|
|
|
|
| LET
16476
|
| Enzymatic Therapy
|
| Vol #:
|
| 147
|
|
|
|
|
| LET
16477
|
| Enzymatic Therapy
|
| Vol #:
|
| 147
|
|
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
|
|
| C 7501
|
| R. Harrison
|
| Vol #:
|
| 319
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| C
384
|
| Briarwood Farms
|
| Vol #:
|
| 32
|
|
|
|
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
|
|
| NM
2
|
| FDA
|
| Vol #:
|
| 5
|
|
|
|
|
| 2004N-0564
|
| Agency Information Collection Activities; Proposed Collection; Temporary Marketing Permit Applications
|
|
|
|
|
| NCR
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
| |
|
| 2005D-0155
|
| Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
|
|
|
|
|
| C
6
|
| Aventis Pasteur, Inc. (Aventis)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005D-0203
|
| Guidance for Industry on Safety Testing of Drug Metabolites
|
|
|
|
|
| C
4
|
| Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| Vol #:
|
| 1
|
|
|
|
|
| C
5
|
| Millennium Pharmaceuticals, Inc. (Millennium)
|
| Vol #:
|
| 1
|
|
